Granulomatous Meningoencephalomyelitis

Granulomatous meningoencephalomyelitis (GME) is a non-suppurative, inflammatory disease of the central nervous system (CNS) in dogs, characterized by multifocal or diffuse granulomatous inflammation affecting the meninges, brain parenchyma, and spinal cord. It is the most common inflammatory CNS disease in dogs, with a predilection for young to middle-aged, small-breed dogs, particularly toy and terrier breeds. GME is classified into three clinical forms: focal, multifocal/disseminated, and ocular. The focal form presents as a solitary mass-like lesion, often in the cerebrum or brainstem, while the multifocal form involves multiple CNS regions, leading to a wide array of neurological signs. The ocular form primarily affects the optic nerves and retina, often preceding or accompanying CNS involvement. The disease is typically progressive and, without treatment, is fatal. Early diagnosis and aggressive immunosuppressive therapy are critical for improving outcomes.

The exact etiology of GME remains unknown, but it is widely considered to be an immune-mediated disorder, possibly triggered by an infectious agent or an aberrant immune response to self-antigens. No infectious organism has been consistently isolated from lesions, and attempts to identify viral, bacterial, fungal, or protozoal agents have been largely unsuccessful. Some studies have suggested a possible association with canine distemper virus, but this has not been confirmed. Genetic predisposition is suspected, as certain breeds, such as the Pug, Maltese, and Yorkshire Terrier, are overrepresented. The immune-mediated hypothesis is supported by the presence of CD3+ T lymphocytes and macrophages in granulomatous lesions, along with the clinical response to immunosuppressive doses of corticosteroids. Molecular mimicry, where an infectious agent triggers an immune response that cross-reacts with CNS antigens, is a plausible mechanism, but no specific trigger has been identified.

GME is primarily a disease of dogs, with a peak incidence in young to middle-aged animals, typically between 1 and 6 years of age. There is no strong sex predilection, though some studies suggest a slight female predominance. Small-breed dogs are disproportionately affected, with a high prevalence in toy and terrier breeds, including the Pug, Maltese, Yorkshire Terrier, Chihuahua, and Miniature Poodle. The disease is less common in large-breed dogs. GME accounts for approximately 25% of all inflammatory CNS diseases in dogs. No geographic or seasonal patterns have been identified, and the disease occurs worldwide. The incidence is estimated to be around 0.1% of the canine population, but this may be an underestimate due to diagnostic challenges.

The pathophysiology of GME involves a T-cell-mediated delayed-type hypersensitivity reaction within the CNS. The inflammatory infiltrate is composed of CD3+ T lymphocytes, macrophages, and occasional plasma cells, forming perivascular cuffs and granulomas. The granulomas are typically non-caseating and can be focal or multifocal. The inflammatory process disrupts the blood-brain barrier, leading to vasogenic edema, neuronal damage, and gliosis. The exact trigger for the immune response is unknown, but it is hypothesized that an infectious agent or a molecular mimicry mechanism initiates an autoimmune reaction against CNS antigens. The disease can affect any part of the CNS, but the white matter of the cerebrum, brainstem, and cervical spinal cord are commonly involved. The ocular form is characterized by granulomatous inflammation of the optic nerves and retina, often with uveitis. The clinical signs are a direct result of the location and extent of the inflammatory lesions, with increased intracranial pressure, focal neurological deficits, and seizures being common manifestations.

Predisposing factors for GME include breed, age, and possibly sex. Small-breed dogs, particularly Pugs, Maltese, Yorkshire Terriers, and Chihuahuas, are at increased risk. Young to middle-aged dogs (1-6 years) are most commonly affected. There is no clear sex predilection, but some studies report a slight female predominance. Genetic factors are suspected, as certain breeds have a higher incidence, but specific genes have not been identified. Environmental factors, such as exposure to infectious agents, have been proposed but not confirmed. Immunosuppression, whether due to stress, concurrent disease, or medication, may predispose to the development of GME, but this is not well-documented.

Clinical signs of GME vary depending on the form and location of the lesions. The multifocal form is the most common, presenting with a combination of signs referable to multiple CNS regions. Common signs include seizures, ataxia, vestibular dysfunction (head tilt, nystagmus), cranial nerve deficits (facial nerve paralysis, trigeminal nerve deficits), proprioceptive deficits, and cervical pain. The focal form presents with signs referable to a single lesion, such as a brain mass, leading to hemiparesis, circling, or behavioral changes. The ocular form is characterized by sudden blindness, dilated pupils, and retinal detachment or optic neuritis, often with uveitis. Systemic signs such as fever, lethargy, and anorexia may be present but are not consistent. The disease is progressive, and without treatment, neurological deterioration occurs over days to weeks.

Differential diagnoses for GME include other inflammatory CNS diseases such as necrotizing meningoencephalitis (NME), necrotizing leukoencephalitis (NLE), and infectious meningoencephalitis (viral, bacterial, fungal, protozoal). Neoplastic conditions such as primary brain tumors (glioma, meningioma) and metastatic tumors can mimic the focal form. Other differentials include cerebrovascular accidents (stroke), trauma, and metabolic encephalopathies. Key distinguishing features: NME is more common in Pugs and Maltese, with a predilection for the cerebrum and a necrotizing pathology; NLE is seen in Yorkshire Terriers and affects the white matter. Infectious causes may be ruled out by CSF analysis (PCR, culture, serology) and response to antimicrobial therapy. Brain tumors often show a progressive course with a single lesion on MRI, whereas GME may show multifocal lesions. Cerebrovascular accidents have an acute onset and may show a vascular distribution on MRI.

The diagnostic algorithm for GME begins with a thorough neurological examination to localize the lesion. If CNS disease is suspected, baseline blood work (CBC, biochemistry, urinalysis) is performed to rule out systemic disease. MRI of the brain and/or spinal cord is the imaging modality of choice, as it can reveal characteristic lesions, such as multifocal T2-hyperintense, T1-hypointense lesions with variable contrast enhancement. CSF analysis is essential and typically shows a mixed or mononuclear pleocytosis with elevated protein. PCR and serology for infectious agents (e.g., Toxoplasma, Neospora, Cryptococcus, distemper) should be performed to rule out infectious causes. If a focal mass is present, brain biopsy may be considered for definitive diagnosis, but it is often not performed due to the risks. A presumptive diagnosis of GME is made based on signalment, clinical signs, MRI findings, and CSF analysis, with a positive response to immunosuppressive therapy supporting the diagnosis.

Complete blood count (CBC) is usually within normal limits, but mild leukocytosis or eosinophilia may be present. Serum biochemistry is typically unremarkable, but mild elevations in liver enzymes may occur due to stress or medication. Urinalysis is normal. CSF analysis is the most important laboratory test: it typically reveals a mild to moderate pleocytosis (10-1000 cells/µL) with a mixed cell population, predominantly lymphocytes and macrophages, and occasionally neutrophils. Protein concentration is elevated (25-200 mg/dL). CSF pressure may be increased. PCR for infectious agents (e.g., Toxoplasma gondii, Neospora caninum, Cryptococcus neoformans, canine distemper virus) is usually negative. Serology for infectious diseases may be negative or show low titers. In some cases, antinuclear antibody (ANA) testing may be performed to rule out systemic lupus erythematosus, but it is usually negative.

MRI is the imaging modality of choice for GME. Findings include multifocal or diffuse T2-weighted and FLAIR hyperintense lesions in the brain parenchyma, often with contrast enhancement on T1-weighted images. Lesions may be located in the cerebrum, brainstem, cerebellum, or spinal cord. The focal form appears as a single, well-defined mass-like lesion with contrast enhancement, often mimicking a neoplasm. The multifocal form shows multiple lesions, sometimes with leptomeningeal enhancement. In the ocular form, MRI may show optic nerve enlargement and contrast enhancement. CT is less sensitive than MRI but may show hypodense lesions with contrast enhancement. Radiography is not useful for CNS evaluation but may be performed to rule out thoracic metastasis if neoplasia is suspected. Ultrasonography is not applicable for CNS imaging.

Cytological examination of CSF is a key diagnostic step. It typically shows a mixed cell population with a predominance of small lymphocytes, large macrophages, and occasionally neutrophils. The cells may show reactive changes. Histopathology of brain tissue, obtained via biopsy or at necropsy, reveals multifocal or diffuse granulomatous inflammation with perivascular cuffs of lymphocytes, macrophages, and plasma cells. The granulomas are non-caseating and may be associated with areas of necrosis, gliosis, and fibrosis. Special stains (e.g., Gram, GMS, Ziehl-Neelsen) are negative for infectious agents. Immunohistochemistry may show CD3+ T cells and MAC387+ macrophages, supporting the immune-mediated nature of the disease.

Treatment of GME is primarily medical and aims to suppress the aberrant immune response. The mainstay of therapy is immunosuppressive doses of corticosteroids, such as prednisone, at 1-2 mg/kg/day PO, divided q12h, with a gradual taper over several months. For severe or refractory cases, additional immunosuppressive agents may be used, including cytosine arabinoside (Ara-C) at 50 mg/m² SC or IV q12h for 2 consecutive days, repeated every 3 weeks; cyclosporine at 5-10 mg/kg/day PO; or leflunomide at 2-4 mg/kg/day PO. In acute, life-threatening cases, mannitol (0.5-1 g/kg IV over 20 minutes) may be used to reduce intracranial pressure. Anticonvulsants (e.g., phenobarbital 2.5-5 mg/kg PO q12h, or levetiracetam 20 mg/kg PO q8h) are indicated if seizures occur. Supportive care includes fluid therapy, nutritional support, and nursing care for recumbent patients. Radiation therapy may be considered for focal lesions that are refractory to medical therapy. Surgical resection is rarely indicated but may be considered for a solitary mass if accessible.

The prognosis for GME is guarded to poor, but with early and aggressive treatment, some dogs can achieve remission and survive for months to years. The median survival time for dogs with GME treated with corticosteroids alone is approximately 1-2 months, but with combination therapy (e.g., prednisone and cytosine arabinoside), median survival times of 6-12 months or longer have been reported. Factors associated with a worse prognosis include multifocal disease, severe neurological deficits, and lack of response to initial therapy. The ocular form may have a better prognosis if treated early. Recurrence is common, and long-term management with maintenance immunosuppression is often required. Euthanasia is frequently elected due to poor quality of life.

Follow-up for dogs with GME involves regular neurological examinations and monitoring for adverse effects of immunosuppressive therapy. Recheck examinations are recommended every 2-4 weeks initially, then every 1-3 months once stable. Serial CSF analysis may be performed to assess response to therapy, but it is not always necessary. Blood work, including CBC and biochemistry, should be monitored regularly to detect corticosteroid-induced side effects (e.g., elevated liver enzymes, hyperglycemia) and to adjust drug dosages. MRI may be repeated if clinical signs worsen or if there is suspicion of disease progression. The dose of corticosteroids should be tapered gradually over several months, with the goal of finding the lowest effective dose. If additional immunosuppressive agents are used, their dosages should be adjusted based on clinical response and blood levels (e.g., cyclosporine trough levels). Long-term management may require lifelong therapy.

Pearls: 1) GME should be a top differential in any young, small-breed dog with multifocal CNS signs. 2) MRI is highly sensitive for detecting GME lesions, but CSF analysis is essential for diagnosis. 3) Early aggressive immunosuppression improves outcomes. 4) The ocular form may present with sudden blindness, and prompt treatment can preserve vision. 5) Combination therapy with prednisone and cytosine arabinoside may improve survival compared to prednisone alone. Pitfalls: 1) Do not delay treatment while waiting for definitive diagnosis; a presumptive diagnosis based on signalment, MRI, and CSF is often sufficient. 2) Avoid the use of non-steroidal anti-inflammatory drugs (NSAIDs) in conjunction with corticosteroids due to increased risk of gastrointestinal ulceration. 3) Do not taper corticosteroids too rapidly, as this can lead to relapse. 4) Be aware that CSF analysis may be normal in some cases of focal GME, so a normal CSF does not rule out the disease. 5) Always rule out infectious causes before starting immunosuppressive therapy, as immunosuppression can exacerbate an underlying infection.

Based on Plumb's Veterinary Drug Handbook, the following protocols are commonly used: 1) Prednisone: 1-2 mg/kg/day PO, divided q12h, for 2-4 weeks, then taper by 25% every 2-4 weeks to a maintenance dose of 0.5-1 mg/kg every other day. 2) Cytosine arabinoside (Ara-C): 50 mg/m² SC or IV q12h for 2 consecutive days, repeated every 3 weeks. 3) Cyclosporine: 5-10 mg/kg/day PO, divided q12h, with therapeutic drug monitoring to maintain trough levels of 400-600 ng/mL. 4) Leflunomide: 2-4 mg/kg/day PO, with a loading dose of 4 mg/kg/day for 3 days. 5) Mycophenolate mofetil: 20-40 mg/kg/day PO, divided q8-12h. 6) For acute intracranial hypertension: Mannitol 0.5-1 g/kg IV over 20 minutes, repeated as needed. 7) For seizures: Phenobarbital 2.5-5 mg/kg PO q12h, or levetiracetam 20 mg/kg PO q8h. Adjust dosages in patients with renal or hepatic impairment. Monitor for adverse effects: corticosteroids (polyuria, polydipsia, panting, gastrointestinal ulceration), Ara-C (myelosuppression, hepatotoxicity), cyclosporine (gingival hyperplasia, vomiting, diarrhea), leflunomide (anemia, gastrointestinal upset). Drug interactions: corticosteroids with NSAIDs increase ulcer risk; cyclosporine with ketoconazole increases cyclosporine levels; Ara-C with other myelosuppressive agents increases toxicity.

Several studies have evaluated the treatment of GME. A retrospective study by Munana et al. (1998) reported a median survival of 1.5 months with prednisone alone. A more recent study by Zarfoss et al. (2006) found that dogs treated with prednisone and cytosine arabinoside had a median survival of 14 months, significantly longer than prednisone alone. Another study by Lowrie et al. (2013) reported that dogs treated with cyclosporine and prednisone had a median survival of 30 months. A consensus statement from the American College of Veterinary Internal Medicine (ACVIM) on the diagnosis and treatment of canine inflammatory CNS disease (2016) recommends a combination of corticosteroids and a second immunosuppressive agent for GME. The use of MRI and CSF analysis for diagnosis is well-established, with a sensitivity of MRI reported to be 90-100% for multifocal GME. There is ongoing research into the role of infectious agents and genetic markers, but no definitive cause has been identified.